|Source||Humanized (from mouse)|
|Target||Proprotein convertase subtilisin/kexin type 9 (PCSK9)|
|Chemical and physical data|
|Molar mass||145.1 kg/mol g·mol−1|
Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|